Company Overview - Immunovant Inc is a clinical-stage immunology company focused on enabling normal lives for people with autoimmune diseases [6] - The company is a trailblazer in anti-FcRn technology, developing innovative, targeted therapies for autoimmune diseases [6] Financing Details - Immunovant has agreed to sell 22,500,000 shares of common stock at $20 00 per share in a private investment in public equity (PIPE) transaction [5] - The PIPE is expected to generate approximately $450 million in gross proceeds [5] - The transaction involves three institutional accredited investors, including a US-based healthcare-focused investor, a large mutual fund complex, and Roivant [4] - The PIPE is expected to close on or about January 15, 2025, subject to customary closing conditions [5] Use of Proceeds - The proceeds from the PIPE will be used to advance the company's development pipeline, working capital, and other general corporate purposes [5] - Specifically, the funds will help advance the development program for the company's lead asset IMVT-1402 [4] Transaction Structure - The shares sold in the PIPE are not registered under the Securities Act of 1933 and are being sold in a transaction not involving a public offering [4] - Immunovant has agreed to register the resale of the shares with the Securities and Exchange Commission [4]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Immunovant, Inc. (IMVT) reported second-quarter fiscal 2025 net loss of 74 cents per share, wider than the Zacks Consensus Estimate of a loss of 61 cents. The reported figure is also wider than the year-ago quarter's loss of 45 cents per share.Currently, Immunovant does not have any approved product in its portfolio. As a result, it has yet to generate revenues.See the Zacks Earnings Calendar to stay ahead of market-making news. IMVT’s Q3 Results in DetailResearch and development (R&D) expenses totaled $97. ...

Table of Contents Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.0001 par value per share IMVT The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission Fil ...

Exhibit 99.1 Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 • Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402 • Proof of concept data from batoclimab trial in Graves' disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs (ATDs); initiatio ...

Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves’ disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs (ATDs); initiation of potentially registrational trial to evaluate IMVT-1402 in GD expected by year endIND cleared for IMVT-1402 in rheumatoid art ...

Monday, Immunovant, Inc. IMVT reported results from the Phase 2a trial of batoclimab in Graves' Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much thyroid hormone. Immunovant is a member of the Roivant Sciences Ltd. ROIV family of companies. Also Read: Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study. As previously disclosed, the batoclimab phase 2a trial in uncontrolled Graves' Disease enrolled patients who were hyperthyroid ...

Shares of Immunovant (IMVT) are rising in the pre-market hours on Sept. 9 after the company announced positive data from the mid-stage study of its investigational candidate, batoclimab, which is being developed for Graves' Disease (GD). IMVT's Batoclimab Shows Superior Efficacy in GD Patients The enrolled patient population of the phase IIa study of batoclimab comprised uncontrolled GD patients who were hyperthyroid despite anti-thyroid drugs (ATD) therapy. Patients were then treated with the high batoclim ...

As of Sept. 9, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to ...

High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12 High dose batoclimab achieved 56% ATD-Free response rate in patients uncontrolled on ATDs at week 12 Strong correlation observed between degree of IgG lowering and clinical outcomes yields potential bestin-class and first-in-class opportunity for IMVT-1402 in Graves' Disease (GD) Real world claims data indicates 25-30% of Graves' Disease patients per year are uncontrolled on ATDs with minimal to n ...